genotropin 16 ui/ml (5,3 mg/ml)
pfizer manufacturing belgium nv - belgia - somatropinum - pulb.+solv. pt. sol. inj. - 16ui/ml(5,3mg/ml) - hormoni ai lobului hipofizar anterior si analogi hormon somatotrop si agonisti ai acestuia
genotropin 16 ui/ml (5,3 mg/ml)
pfizer europe ma eeig - somatropinum - pulb. + solv. pt. sol. inj. - 16ui/ml(5,3mg/ml) - hormoni ai lobului hipofizar anterior si analogi hormon somatotrop si agonisti ai acestuia
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
solu - medrol act-o-vial
pfizer manufacturing belgium n.v. - belgia - alprazolamum - liof. si solv.pt.sol.inj - 250mg/4ml - corticosteroizi sistemici glucocorticoizi
latanoprost stada hf 50 micrograme/ml
hbm pharma s.r.o. - republica slovaca - latanoprostum - pic. oft., sol. - 50 micrograme/ml - antiglaucomatoase si miotice analogi de prostaglandine
mydrane 0,2 mg/ml+3,1 mg/ml+10 mg/ml
delpharm tours - franta - combinatii (tropicamidum+phenylephrinum+lidocainum) - sol. inj. - 0,2mg/ml+3,1mg/ml+10mg/ml - midriatice si cicloplegice anticholinergice
gonal-f 900 ui (66 mcg) soluţie injectabilă în stilou injector preumplut
merck europe b.v. - follitropinum alfa - soluţie injectabilă în stilou injector preumplut - 900 ui (66 mcg)
gonal-f 450 ui (33 mcg) soluţie injectabilă în stilou injector preumplut
merck europe b.v. - follitropinum alfa - soluţie injectabilă în stilou injector preumplut - 450 ui (33 mcg)
gonal-f 300 ui (22 mcg) soluţie injectabilă în stilou injector preumplut
merck europe b.v. - follitropinum alfa - soluţie injectabilă în stilou injector preumplut - 300 ui (22 mcg)
olynth 0,5 mg/ml
delpharm orleans - franta - xylometazolinum - spray naz.,sol. - 0,5mg/ml - decongestionante si alte medicamente nazale de uz topic simpatomimetice